New HIV prevention strategy for pregnant women could eliminate need for common drugs
NCT ID NCT02738502
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single HIV drug, darunavir/ritonavir, could replace the usual combination therapy in pregnant women with well-controlled HIV. The goal was to prevent mother-to-child transmission without using a class of drugs called NRTIs. 91 pregnant women already on HIV treatment and with undetectable virus levels participated. The approach aims to simplify treatment while keeping the baby safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darunavir/ritonavir (DRV/r) monotherapy
What this could lead to
If successful, this could offer a simpler, NRTI-free treatment option for pregnant women with HIV to prevent mother-to-child transmission.
What could go wrong
This is a small, early-phase pilot study with only 91 participants, so results may not apply broadly. The monotherapy may fail to keep viral load suppressed, risking transmission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATERNAL-FETAL INFECTION TRANSMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Victor Dupouy
Argenteuil, 95100, France
-
CHU Archet 1
Nice, 06202, France
-
CHU Rennes Hôpital Pontchaillou
Rennes, 35000, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU de Perpignan
Perpignan, 66046, France
-
Groupe hospitalier Cochin-Broca- Hôtel Dieu
Paris, 75014, France
-
Groupe hospitalier Pellegrin
Bordeaux, 33000, France
-
HEGP
Paris, 75015, France
-
Hôpital Antoine Béclère
Clamart, 92140, France
-
Hôpital Armand Trousseau
Paris, 75012, France
-
Hôpital Bichat - Claude Bernard
Paris, 75018, France
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, 94275, France
-
Hôpital Foch
Suresnes, 92151, France
-
Hôpital Jean Verdier
Bondy, 93140, France
-
Hôpital Lariboisiere
Paris, 75010, France
-
Hôpital Louis Mourier
Colombes, 92700, France
-
Hôpital Necker Enfant malades
Paris, 75015, France
-
Hôpital Saint André
Bordeaux, 33075, France
-
Hôpital Sud Francilien
Corbeil-Essonnes, 91106, France
-
Hôpital Tenon
Paris, 75020, France
-
Hôpital de la croix Rousse
Lyon, 69307, France
-
Hôpital la Pitié Salpétrière
Paris, 75013, France
-
Hôtel Dieu
Nantes, 44093, France